

# OPTIMISE YOUR PATIENT'S TREATMENT SEQUENCE

WITH **GIOTRIF**<sup>®1</sup>



**APPROXIMATELY 60% OF PATIENTS  
WITH COMMON MUTATIONS WHO ACQUIRE  
A RESISTANCE TO GIOTRIF<sup>®</sup> IN 1<sup>ST</sup>-LINE  
WILL HAVE A T790M MUTATION<sup>2,3</sup>**

**References:** 1. Girard N. Future Oncol 2018;14:1117-1132

2. Hochmair MJ et al. Target Oncol 2019;14:75-83.

3. Yang JC, et al. J Clin Oncol 2017;35:1288-1296.



**Boehringer  
Ingelheim**

**Boehringer Ingelheim Singapore Pte. Ltd.**

128 Beach Road

#11-01 Guoco Midtown, Singapore 189773

Phone: +65 / 6419 8600

Fax: +65 / 6297 5771



Scan QR code to access **GIOTRIF<sup>®</sup>**  
latest prescribing information

EM-SG-100100 June 2023 | For Healthcare Professionals Only